Novavax, a developer of recombinant nanoparticle vaccines and adjuvants, has announced the appointment of John Trizzino as Senior Vice President, Commercial Operations.
Trizzino, who joined the company today (10 March), will be responsible for developing and implementing the commercialisation strategy in support of the company's product candidates, including its RSV F, quadrivalent seasonal and pandemic influenza vaccine candidates.
Trizzino previously served as Novavax' Senior Vice President of International and Government Alliances beginning in 2009 and its Senior Vice President of Business Development from 2010 to 2011. In these roles, he played a key role in negotiating the company's US$179m contract with HHS BARDA.
Most recently he was CEO at Immunovaccine, and prior to his time at Novavax, served as Vice President of the Vaccine Franchise at MedImmune, Senior Vice President of Business Development at ID Biomedical and Vice President of Business Development at Henry Schein.
'Novavax is at an important milestone in the development of its RSV, seasonal influenza and pandemic influenza vaccines. As these vaccine candidates move into the later stages of clinical development it is the right time to develop a commercialization strategy to ensure a successful path to market,' said Trizzino.
'I am looking forward to working with the Novavax team again in pursuit of these and the other vaccine candidates in its pipeline.'
